Associated Genetic Biomarkers
COL6A3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains COL6A3 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with COL6A3 status in the inclusion eligibility criteria most commonly target ovarian carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is COL6A3 Expression .
Cd8+ t-cell therapy, aldesleukin, cyclophosphamide, and utomilumab are the most frequent therapies in trials with COL6A3 as an inclusion criteria .
Significance of COL6A3 in Diseases
Ovarian Carcinoma +
COL6A3 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains COL6A3 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.